ACRS

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Aclaris Therapeutics Inc

NASDAQ | ACRS

2.04

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 16, 2025)

$209.08M

Market Cap

-

P/E Ratio

-1.57

EPS

$5.17

52 Week High

$1.05

52 Week Low

HEALTHCARE

Sector

ACRS Chart

Recent Chart
Price Action

ACRS Technicals

Tags:

ACRS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $16M
Total Revenue $19M
Cost Of Revenue $2.8M
Costof Goods And Services Sold $2.8M
Operating Income -$142M
Selling General And Administrative $22M
Research And Development $34M
Operating Expenses $158M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $807K
Income Before Tax -$132M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$132M
Comprehensive Income Net Of Tax -
Ebit -$53M
Ebitda -$52M
Net Income -$132M

Revenue & Profitability

Earnings Performance

ACRS Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $220M
Total Current Assets $126M
Cash And Cash Equivalents At Carrying Value $25M
Cash And Short Term Investments $25M
Inventory -
Current Net Receivables $318K
Total Non Current Assets $94M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $90M
Short Term Investments $89M
Other Current Assets $12M
Other Non Current Assets -
Total Liabilities $65M
Total Current Liabilities $32M
Current Accounts Payable $4.7M
Deferred Revenue -
Current Debt -
Short Term Debt $962K
Total Non Current Liabilities $33M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $2.6M
Other Current Liabilities $22M
Other Non Current Liabilities $13M
Total Shareholder Equity $156M
Treasury Stock -
Retained Earnings -$903M
Common Stock $1K
Common Stock Shares Outstanding $77M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$20M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $807K
Capital Expenditures $121K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$70M
Cashflow From Financing $75M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$132M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $16M
Total Revenue $19M
Cost Of Revenue $2.8M
Costof Goods And Services Sold $2.8M
Operating Income -$142M
Selling General And Administrative $22M
Research And Development $34M
Operating Expenses $158M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $807K
Income Before Tax -$132M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$132M
Comprehensive Income Net Of Tax -
Ebit -$53M
Ebitda -$52M
Net Income -$132M

ACRS News

ACRS Profile

Aclaris Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Wayne, Pennsylvania, dedicated to the development of pioneering small molecule therapies targeting immuno-inflammatory diseases. With a robust pipeline featuring candidates in various stages of clinical trials, Aclaris aims to address significant unmet medical needs through its innovative research and development capabilities. The company’s commitment to advancing patient care is further reinforced by strategic partnerships, solidifying its position as an emerging leader in the biopharmaceutical sector.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.17%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
AADI
+24.28%
$2.61
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
BTG
+3.96%
$5.89
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
ABAT
-36.64%
$5.67
NAK
-4.34%
$2.64
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
BAC
-4.03%
$50.17
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.34%
$0.43
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-5.05%
$51.08
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.17%
$11.74
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
AADI
+24.28%
$2.61
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
BTG
+3.96%
$5.89
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
ABAT
-36.64%
$5.67
NAK
-4.34%
$2.64
HBAN
-5.18%
$15.37
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
CLSK
-13.83%
$19.98
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
HIMS
-5.75%
$59.15
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
BAC
-4.03%
$50.17
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.34%
$0.43
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-5.05%
$51.08
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.